INTRODUCTION {#s1}
============

The calpain family of cysteine proteases mediates intracellular regulatory proteolysis in response to calcium signaling ([@MCS002519VELC4]). Increased calpain protease activity is associated with numerous pathologies, such as myocardial infarction, stroke, diabetes, thrombosis, neuronal injury, and neurodegeneration ([@MCS002519VELC2]; [@MCS002519VELC11]; [@MCS002519VELC24]; [@MCS002519VELC18]). The only inherited calpain disease characterized by protease hyperactivity is autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV; OMIM \#193235), which is due to mutations in *CAPN5.* Despite the widespread expression of *CAPN5* ([@MCS002519VELC8]; [@MCS002519VELC7]; [@MCS002519VELC29]; [@MCS002519VELC25]), to date only ophthalmological manifestations have been reported in ADNIV. In their second or third decade, ADNIV patients develop intraocular inflammation (uveitis) and retinal signaling defects ([@MCS002519VELC14]). The disease continues to progress sequentially through a series of pathological stages, each sharing characteristics with common eye diseases (e.g., retinitis pigmentosa, proliferative diabetic retinopathy, and proliferative vitreoretinopathy), ultimately culminating in blindness in the fifth decade. Here we report a child with early-onset, severe inflammatory vitreoretinopathy, profound hearing loss, and developmental delay associated with a novel de novo *CAPN5* mutation.

RESULTS {#s2}
=======

The proband ([Fig. 1](#MCS002519VELF1){ref-type="fig"}A) presented to us at the age of 10 yr with end-stage chronic uveitis and progressive sensorineural hearing loss. He had no light perception in both eyes. There was bilateral band keratopathy ([Fig. 1](#MCS002519VELF1){ref-type="fig"}B,C) without any view to the posterior pole. Ultrasound B-scans showed a silicon-filled right eye and a phthisical left eye ([Fig. 1](#MCS002519VELF1){ref-type="fig"}D,E). His visual issues were first noted at age 2, where he showed vertical nystagmus, bilateral pupillary membranes, anterior and posterior inflammatory cells, retinal membranes, and optic disc edema. His magnetic resonance imaging (MRI), which revealed thickening of the optic chiasm and enhancement affecting the prechiasmatic optic nerves, was consistent with optic neuritis ([Fig. 1](#MCS002519VELF1){ref-type="fig"}F). Over the next several years, he underwent multiple procedures to treat recurrent pupillary membranes, cataracts, glaucoma, and retinal detachment. His uveitis was treated with ocular prednisolone, atropine, and a short trial of oral methotrexate. By age 5, he had lost all vision and his eyes were prephthisical. Follow-up MRIs revealed resolution of optic neuritis but mild chronic ocular inflammation ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1)).

![Clinical examination of a patient with inflammatory vitreoretinopathy, hearing loss, and developmental delay. (*A*) Pedigree of the affected proband. Black symbols represent clinically affected subjects. Open symbols represent unaffected subjects. Both parents had normal eye and hearing exams. There were no extended family members with similar vision loss, sensorineural hearing loss, neurologic disorder, or developmental delay. (*B*,*C*) External photo showing bilateral band keratopathy. B-scan ultrasonography showed a (*D*) silicon-filled right eye and (*E*) phthisical left eye. (*F*) T2-weighted MRI imaging of the proband at age 2 (no fat suppression) reveals that optic chiasm thickening and enhancement affecting the prechiasmatic optic nerves was consistent with optic neuritis. (*G*) Audiogram at age 10 reveals significant sensorineural hearing loss.](MCS002519Vel_F1){#MCS002519VELF1}

The patient met his developmental milestones until the age of 2 yr, but has he had developmental delays with regard to language, socialization, and quantitative reasoning. He had displayed slow progression in his learning, which appeared to plateau in the most recent years. There was less delay in the patient\'s gross motor development, although he was noted to have mild truncal hypotonia and displayed repetitive hand motions. He had unexplained behavioral outbursts, therefore an electroencephalography (EEG) was performed. EEG showed nonspecific temporal lobe abnormalities as well as generalized low-amplitude β frequency activity. Hearing difficulties began at age 6, and audiograms revealed mild high- to mid-range sensorineural hearing loss. There was progressive decline in his hearing from mild, to moderate, to severe, requiring hearing aids ([Fig. 1](#MCS002519VELF1){ref-type="fig"}G). He had lifelong gastrointestinal difficulties, including episodes of chronic diarrhea and constipation, without a clear etiology. A brain MRI showed normal inner ear structures and seventh and eighth cranial nerves, bilateral phthisis bulbi, and no optic nerve enhancement ([Supplemental Fig. 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1)).

We performed whole-exome sequencing (WES) on this patient and the unaffected parents. Samples were sequenced with a mean depth of coverage of 104× ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1)). Bidirectional sequences were assembled, aligned to reference gene sequences based on GRCh37/UCSC hg19, and analyzed for sequence variants using XomeDx software (GeneDx). We identified 140,798 coding variants in the proband ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1)). Variants were then filtered based on predicted loss-of-function or missense mutation, the presence of gene or variant in the Human Gene Mutation Database, and minor allele frequency (MAF) of \<0.01 ([@MCS002519VELC31]). MAFs were obtained from the 1000 Genomes Project using the Ensembl Variant Effect Predictor (VEP) tool ([@MCS002519VELC15]).

The proband harbored a de novo, heterozygous, missense variant in the *CAPN5* gene (NM_004055.4), c.865C\>T, p.Arg289Trp ([Table 1](#MCS002519VELTB1){ref-type="table"}). For this gene, 98.9% of the coding region was covered at a minimum of 10×. Other mutations in *CAPN5* are associated with autoinflammatory disease restricted to the eye ([@MCS002519VELC14]; [@MCS002519VELC3]; [@MCS002519VELC23]). In view of the patient\'s extraocular phenotype, additional review of 133 genes associated with sensorineural hearing loss, global developmental delay, and Usher syndrome was performed ([Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1); [@MCS002519VELC26]; [@MCS002519VELC16]). Identified variants in these genes were reviewed for inheritance pattern, phenotypic correlation, and predicted loss of function. These remaining candidate variants were either predicted to be tolerated by SIFT and PolyPhen-2 analysis or did not match the mode of inheritance for their respective phenotype ([Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1); [@MCS002519VELC28]; [@MCS002519VELC1])

###### 

*CAPN5* variant information

  Gene      Chr: position GRCh37 (hg19)   HGVS DNA reference   HGVS protein reference   Gene coverage    Variant read depth  Variant type   Genotype       ClinVar accession   Inheritance
  --------- ----------------------------- -------------------- ------------------------ --------------- -------------------- -------------- -------------- ------------------- -------------
  *CAPN5*   Chr 11: 76826606              c.865C\>T            p.Arg289Trp              98.9%                   10×          Missense       Heterozygous   SCV000329671.5      De novo

The patient\'s mutation and constellation of symptoms suggested an underlying autoinflammatory disease and prompted further rheumatologic and neurophysiologic evaluation. With the recent auditory and behavioral decline, the patient was started on monthly intravenous immunoglobulin (IVIG), high-dose steroids followed by 3 mo of oral prednisolone, which appeared to stabilize his hearing loss. Eight months later, mycophenolate mofetil was added. Despite 15 mo of treatment, his hearing continued to decline, and he became profoundly deaf in both ears.

*CAPN5* encodes the protein calpain-5 (CAPN5), an intracellular calcium-activated cysteine protease with evolutionarily conserved domains and residues required for its activity. CAPN5\'s catalytic core is encoded by exon 6, where we previously identified three disease-causing mutations ([Fig. 2](#MCS002519VELF2){ref-type="fig"}A). The new c.865C\>T variant mutates Arg289, which is five residues away from a catalytic residue (Asn284) and only three residues away from a highly conserved residue (Trp286). Arg289 is conserved in 70% of CAPN5 orthologs but poorly conserved among human paralogs ([Fig. 2](#MCS002519VELF2){ref-type="fig"}B).

![The *CAPN5* gene harbors a novel mutation in domain II. (*A*) CAPN5 is composed of four domains, and the novel mutation was located in catalytic domain II (violet). (*B*) Primary protein sequence alignment of calpain-5 orthologs shows 70% evolutionary conservation of the new mutated p.Arg289Trp residue, along with the three prior ADNIV mutations, p.Arg243Leu, p.Leu244Pro, and p.Lys250Asn (magenta arrow), in catalytic domain IIb. (*C*) Alignment of 13 human calpain family paralogs show the p.Arg289Trp is poorly conserved (15%).](MCS002519Vel_F2){#MCS002519VELF2}

We generated a structural model for CAPN5 ([@MCS002519VELC9]). Three ADNIV mutations are located on a flexible loop (G1 loop) ([Fig. 3](#MCS002519VELF3){ref-type="fig"}A) that undergoes calcium-induced conformation changes during enzyme activation ([@MCS002519VELC17]; [@MCS002519VELC4]). This loop is located on the amino-terminal side of the catalytic groove and acts as a gatekeeper to control substrate access ([Fig. 3](#MCS002519VELF3){ref-type="fig"}A). The first three CAPN5 mutants significantly alter the G1 loop structure ([@MCS002519VELC14]; [@MCS002519VELC3]). The new *CAPN5* mutation (p.Arg289Trp) is located on a complementary flexible loop (G2 loop) on the carboxy-terminal side of the catalytic groove. Introduction of the mutant tryptophan places it near three other tryptophans, which can engage in noncovalent π--π stacking interactions. One of these tryptophans (Trp286) is the critical "wedge" tryptophan that inhibits enzymatic activity by inserting itself in the catalytic groove to prevent bonding between the catalytic triad ([Fig. 3](#MCS002519VELF3){ref-type="fig"}B; [@MCS002519VELC17]). Normally, only calcium-induced conformational changes remove this inhibitory wedge from the active site ([Fig. 3](#MCS002519VELF3){ref-type="fig"}C). Tryptophan has strong stacking interactions because of the large surface area and dipole moment of its side chain ([@MCS002519VELC22]). This property has been exploited in the design of α-ketoamide inhibitors for CAPN1 and CAPN2. These compounds (e.g., ZLAK-3001 and ZLAK-3002) contain adenine and piperazyl side chains that stabilize the inhibitory tryptophan wedge in the inactive state ([@MCS002519VELC22]). Our model indicated introduction of an additional tryptophan on the G2 loop could cause stacking interactions that stabilize the Trp286 "wedge" in calpain\'s active conformation ([Fig. 3](#MCS002519VELF3){ref-type="fig"}D). Disrupting this regulatory mechanism could lead to reduced calcium requirements for activation.

![The p.Arg289Trp mutation causes calpain hyperactive proteolysis. (*A*) Structural model of the inactive CAPN5 catalytic core generated using closely related CAPN9 (PDB ID: 1ZIV) as a template. The catalytic core is comprised of two globular subdomains (DIIa and DIIb) separated by a flexible linker. Movement of DIIa and DIIb with respect to the linker region regulates formation of the active site. The catalytic residues (yellow) are in the active site groove. The G1 gating loop (green) contains previously identified ADNIV mutations (p.Arg243Leu, p.Leu244Pro, p.Lys250Asn; magenta). The G2 gating loop (pink) contains the novel p.Arg289Trp mutation along with the Trp286 "wedge" residue (blue) and three additional tryptophans. (*B*) Close-up view of the CAPN5 catalytic groove in its inactive state. In the absence of activating calcium, the Trp286 residue acts as a wedge and prevents the formation of the catalytic triad. (*C*) Close-up view of the CAPN5 catalytic groove in its active state modeled off CAPN9 (PDB ID: 2P0R). Calcium binding causes a structural rearrangement that removes the Trp286 "wedge" away from the active site and facilitates the formation of the catalytic triad. (*D*) Tryptophans engage in π--π stacking interactions. Substitution of Arg289 with Trp on the G2 gating loop may cause stacking interactions that stabilize the Trp286 "wedge" in its active conformation. Disruption of this inhibitory mechanism may reduce the calcium requirement for CAPN5 activation and lead to hyperactive proteolysis of substrates in affected tissues. (*E*) Whereas wild-type and inactive versions (p.Cys81Ser) of CAPN5 show no autoproteolytic activity at normal cellular calcium levels, the syndromic CAPN5 p.Arg289Trp mutant displays autoproteolytic activity. This proteolytic activity is higher than that observed for the nonsyndromic CAPN5 p.Arg243Leu mutant. (*F*) Close-up view of the crystal structure of active rat CAPN1 (PDB ID: 1KXR) shows similarities to our CAPN5 homology model. (*G*) A homologous mutation (p.Val301Trp) to p.Arg289Trp was introduced to purified recombinant rat CAPN1, which resulted in increased enzymatic activity compared to wild type in a fluorescence-based enzymatic assay. Results are reported as initial velocity versus substrate (EPLFAERK) concentration.](MCS002519Vel_F3){#MCS002519VELF3}

We used CAPN5 autoproteolysis to measure its proteolytic activity, because CAPN5 does not proteolyze known calpain substrates ([@MCS002519VELC35]). Increased intracellular calcium triggers calpain activation and subsequent autoproteolysis and release of calpain\'s catalytic core ([@MCS002519VELC4]). We expressed CAPN5 mutants in cells to determine their activity ([Fig. 3](#MCS002519VELF3){ref-type="fig"}E). At normal intracellular calcium, both a catalytically inactive mutant (p.Cys81Ser) and the wild-type (WT) CAPN5 were inactive. The p.Arg243Leu mutant showed slight activation, whereas the p.Arg289Trp disease variant showed strong activation. Thus, CAPN5 p.Arg289Trp was hyperactive, autoproteolyzed even in the absence of calcium levels required to activate WT CAPN5, and displayed more proteolytic fragments than p.Arg243Leu ([Fig. 3](#MCS002519VELF3){ref-type="fig"}E; [Supplemental Fig. 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1)), consistent with the more severe phenotype seen in our proband. At elevated intracellular calcium, the WT CAPN5 became activated as expected, and the p.Arg289Trp maintained high hyperactivity (data not shown). Interestingly, introduction of the homologous mutation (p.Val301Trp) ([Fig. 3](#MCS002519VELF3){ref-type="fig"}F) ([@MCS002519VELC17]) into purified CAPN1 catalytic core also led to increased enzymatic activity, further confirming that disruption of the Trp "wedge" by this mutation is a critical, conserved regulatory mechanism across calpains ([Fig. 3](#MCS002519VELF3){ref-type="fig"}G; [Supplemental Fig. 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1)).

DISCUSSION {#s3}
==========

In this report, we present a 10-yr-old boy with a novel *CAPN5* mutation (p.Arg289Trp) that is associated with early-onset severe inflammatory vitreoretinopathy, optic neuritis, sensorineural hearing loss, developmental delay, mild nonspecific EEG abnormalities, and GI disturbances. The clinical phenotype in this patient is distinct from previous ADNIV kindreds ([@MCS002519VELC14]; [@MCS002519VELC3]; [@MCS002519VELC23]). In these families, disease onset did not begin until the second decade of life, there was no optic neuritis, and blindness typically occurred after the fifth decade. These ADNIV pedigrees did not manifest disease outside the eye, despite *CAPN5* expression during embryogenesis, in the colon, kidney, liver, trachea, uterus, thymus, and subsets of CNS neurons ([@MCS002519VELC8]; [@MCS002519VELC7]; [@MCS002519VELC29]; [@MCS002519VELC25]).

The proteotype--phenotype difference between previous ADNIV kindreds and the proband is noteworthy. Nonsyndromic ADNIV patients affected by G1 loop mutations have a nearly identical phenotype. The earlier onset and more severe phenotype associated with p.Arg289Trp is in a different region of the protein (G2 loop). The p.Arg289Trp falls into a peptide loop that changes conformation upon calcium binding, similar to prior ADNIV mutations ([@MCS002519VELC22]; [@MCS002519VELC14]; [@MCS002519VELC3]). This finding indicates a functional proteotype--phenotype correlation for *CAPN5* mutations in which the disease severity follows the level of protease hyperactivity. In fact, the structural mechanisms seem to be conserved across calpains and can be used to infer functional consequences on other isoforms. Interestingly, variants in the CAPN5 G2 loop have been previously reported in the GnoMAD browser, suggesting that some mutations in this region of the protein may be tolerated ([Supplemental Table 5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1); [@MCS002519VELC13]). However, none of these variants add an additional tryptophan residue that would similarly disrupt the regulatory mechanism of the G2 loop.

The presence of sensorineural hearing loss in our patient is interesting, as CAPN5 has not been found to be expressed in cochlear hair cells ([@MCS002519VELC33]). The auditory and CNS phenotype may be due to synaptic signaling defects, because CAPN5 has been found to be expressed in neuronal synapses and mitochondria. These compartments are rich in calcium and may be susceptible to damage by a hyperactive CAPN5 ([@MCS002519VELC34]). The combination of hearing loss and blindness recalls Usher syndrome. However, identified variants in genes associated with Usher syndrome, sensorineural hearing loss, and developmental delay in our patient were predicted to be nonpathogenic ([Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1); [@MCS002519VELC20]). Dysfunction in these systems may be due to dysregulation of other calpain effector pathways, such as synaptic signaling, or late clinical examination may have missed these signs. Maintenance of gut pacemaker activity is heavily dependent on intracellular calcium signaling and dysregulation is associated with gut motility dysfunction ([@MCS002519VELC32]).

In summary, our findings suggest that the *CAPN5* mutation in this patient may be biologically more pathogenic than those identified in previous ADNIV kindreds. This also suggests that hyperactive CAPN5 can cause disease in other tissues and that it is involved in numerous pathological pathways. There is some precedent for this, as increased calpain activity has been implicated in other autoinflammatory diseases. The presence of a single patient with the described mutation limits the conclusions of the current study. Thus, identification of additional patients harboring the p.Arg289Trp mutation will add confidence to our findings and further expand the ADNIV phenotype. Although unlikely, we cannot exclude the possibility that the patient\'s sensorineural hearing loss is due to an additional identified variant ([Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1)). Nevertheless, these mutations would not account for all the patient\'s extraocular phenotypes, such as developmental delay and GI disturbance. Developmental delay is multifactorial and may be explained by an additional unknown genetic variant or environmental factor ([@MCS002519VELC30]). Further, we did not account for potential copy-number variants (CNVs) or gene deletions, which are known to contribute to a large percentage of hearing loss and developmental delay cases ([@MCS002519VELC5]; [@MCS002519VELC19]; [@MCS002519VELC27]; [@MCS002519VELC10]). Additionally, although neither parent was found to carry the p.Arg289Trp likely pathogenic variant, the possibility of germline mosaicism cannot be excluded in this case. Finally, although 95.3% of the exomes were covered with at least 10 sequence reads, we cannot rule out the possibility that a small portion of the target region was not covered with sufficient depth or quality to confidently call some variant positions. Therefore, we anticipate that further mechanistic studies on CAPN5 function in different tissues may validate this novel variant and offer therapeutic insight into various diseases.

METHODS {#s4}
=======

Study Approval {#s4a}
--------------

The study was approved by the University of Iowa\'s Institutional Review Board and adheres to the tenets set forth in the Declaration of Helsinki. Informed consent was obtained from study participants. The subject underwent eye exams that included slit-lamp examination, dilated retinal biomicroscopy, indirect ophthalmoscopy, and B-scan ultrasonography. MRI examination of the brain was performed utilizing axial T2 weighted images obtained prior to and following intravenous Gadolinium DTPA administration. In addition, axial and coronal T2 weighed, axial diffusion weighted and axial FLAIR images of the posterior periventricular white matter were obtained. This was supplemented with sagittal and coronal T1 weighted Gadolinium enhanced images.

Whole-Exome Sequencing and Analysis {#s4b}
-----------------------------------

Genomic DNA from the proband and parents were processed using the Agilent Clinical Research Exome kit. The targeted regions (exonic regions and flanking splicing junctions) were sequenced simultaneously by massively parallel (NextGen) sequencing on an Illumina HiSeq sequencing system with 100-bp paired-end reads with a mean depth of coverage of 104× (quality threshold 95.3%) ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1)). Bidirectional sequences were assembled, aligned to reference gene sequences based on GRCh37/UCSC hg19, and analyzed for sequence variants using XomeDx software (GeneDx). Variants were filtered based on predicted loss-of-function or missense mutation, presence of gene or variant in the Human Gene Mutation Database, and MAF of \<0.01 ([@MCS002519VELC31]). MAFs were obtained from the 1000 Genomes Project using the Ensembl Variant Effect Predictor (VEP) tool. The remaining variants were analyzed by SIFT and PolyPhen-2 ([Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002519/-/DC1); [@MCS002519VELC28]; [@MCS002519VELC1]). Capillary sequencing was used to confirm all potentially pathogenic variants identified in the proband and parent samples. The identified variant was submitted to ClinVar (ID 279987) ([@MCS002519VELC12]).

Structural Modeling of CAPN5 {#s4c}
----------------------------

Primary and secondary structure protein alignments and trees were created with Geneious R10 and visualized using ESPript 3.0. Homology models were generated for the human calpain-5 catalytic core using MODELLER 9.14, as previously described ([@MCS002519VELC3]; [@MCS002519VELC9]). The structures of human calpain-9 (42% sequence identity) were used as templates (PDB ID 2P0R; calcium and leupeptin bound closed and PDB ID 1ZIV; calcium and β-mercaptoethanol bound open) ([@MCS002519VELC6]). Ten models were generated off each template. Because there was little variation around the ADNIV mutation sites, we chose the top models from each template generated by MODELLER for figures. To better visualize the G2 gating loop, five different conformations of the loop (residues 286--320) were generated using the refinement function of the MODELLER graphical user interface in UCSF Chimera ([@MCS002519VELC21]). PyMOL was used to generate all structure figures.

Cell Transfections {#s4d}
------------------

Of note, 6 × 10^5^ HEK-293T cells (ATCC) were seeded into each well of six-well plates and grown overnight in Dulbecco\'s modified Eagle medium (DMEM, GIBCO) supplemented with 10% fetal bovine serum (GIBCO), 1% penicillin--streptomycin (10,000 U/ml; GIBCO). After 24 h, vectors were transfected into cells using PolyFect (QIAGEN) as per the manufacturer\'s protocol. Cells were incubated for 24 h before being harvested by lysis in 200 µl of TNE buffer (50 mM Tris, 100 mM NaCl, 5 mM EDTA).

Western Blots {#s4e}
-------------

Protein levels were detected by western blotting. Total cellular protein was measured using NanoDrop 2000c (ThermoScientific). Reactions were carried out with 4× LDS-sample buffer, 10× reducing agent and equal amounts of protein. Reactions were denatured for 5 min at 90°C. Samples were then separated electrophoretically on a 15-well 4%--12% Bis--Tris gel (Life Sciences) and transferred onto a nitrocellulose membrane using an iBlot dry blotting system (ThermoScientific). Proteins were immunostained with anti-CAPN5 (GTX103264, GeneTex; 1: 1000 dilution) and anti-GAPDH (sc-25778, Santa Cruz Biotechnology; 1: 1000 dilution) and goat anti-rabbit secondary antibody (sc-2004, Santa Cruz Biotechnology; 1: 1000 dilution). The immunoreactive bands were detected with Supersignal West Dura Extended Duration Substrate (ThermoScientific). Visualization was performed with MYECL Imager (ThermoScientific).

Cloning {#s4f}
-------

The rat CAPN1 WT and p.V301W catalytic core sequences were cloned into a pUC57 vector with an XhoI restriction site, with an amino-terminal thrombin cleavage site and a carboxy-terminal TEV protease cleavage site followed by a 6xHis tag, as previously described ([@MCS002519VELC17]; [@MCS002519VELC9]). Calpain constructs were transferred into the pMAL-C5X vector to obtain an amino-terminal maltose-binding protein (MBP) as a fusion partner. Sequence of the calpain-flanking regions was confirmed by sequencing of constructs. Plasmids were amplified and isolated from DH5α cells and then were transformed into *Escherichia coli* BL21 (DE3; New England Biolabs).

Protein Purification {#s4g}
--------------------

*Escherichia coli* BL21 (DE3; New England Biolabs) cells expressing rat CAPN1 WT and p.V301W catalytic core sequences were grown in 1 l shake-flask cultures, at 250 rpm in Terrific Broth (Invitrogen), at 37°C until an OD~600~ of 2.0 and then induced with 0.2 mM IPTG (Sigma-Aldrich). Cells were grown for 19 h at 16°C , harvested, and centrifuged at 4000*g* for 20 min and pellet frozen at −20°C. Cells were resuspended in 35 ml of lysis buffer (20 mM Tris, 300 mM NaCl, 1 mM DTT, pH 7.5) and one tablet of EDTA-free protease inhibitor (Roche) and lysed using sonicator (Fisher Scientific Model 705) and centrifuged for 1 h at 18,000 RPM. Cell debris were discarded and the supernatant (30 ml) loaded onto a column packed with 5 ml (1CV) amylose resin (New England Biolabs). The column was washed with 12 CV of wash buffer (20 mM Tris, 300 mM NaCl, pH 7.5) and eluted with 6 CV of elution buffer (20 mM Tris, 300 mM NaCl, 10 mM maltose, pH 7.5). Eluted fractions were pooled and concentrated to 2 ml at 10 mg/ml (30 kDa NMWL spin concentrator; Millipore) and passed over a Superdex 200 (GE) size-exclusion column to remove residual impurities. The column was equilibrated with 20 mM Tris, 300 mM NaCl, 2 mM DTT, pH of 7.5. The final sample was concentrated with a 30 kDa NMWL spin concentrator and stored in 50% glycerol at −80°C before use.

Proteolysis Assay {#s4h}
-----------------

Purified calpain activity was measured by cleavage of a FRET-tagged calpain peptide substrate (EPLFAERK; Biopeptek) as previously described ([@MCS002519VELC35]). Briefly, 5 µg of purified calpain was added to a reaction buffer containing 20 mM Tris, 300 mM NaCl, 2 mM DTT, and 1 mM CaCl~2~ (pH 7.5). Different concentrations of substrate (0--100 µM) were added and the reaction was incubated for 15 min at 37°C. Proteolysis was quantified as raw fluorescence units on a fluorimetric plate reader (Tecan Spark).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The *CAPN5* variant has been registered in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000329671.5. Patient consent could not be obtained for deposition of raw sequencing data.

Ethics Statement {#s5b}
----------------

The study was approved by the University of Iowa\'s Institutional Review Board and adheres to the tenets set forth in the Declaration of Helsinki. Informed consent was obtained from study participants. Both the patient and his parents have consented to publication of this case history with patient pictures.
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